Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Arch Dis Child. 2022 Feb;107(2):128-133. doi: 10.1136/archdischild-2020-321216. Epub 2021 Jul 6.
To assess the efficacy of oral low-level laser therapy (LLLT) - also known as photobiomodulation - in the reduction of oral mucositis experienced by children and young people with cancer undergoing chemotherapy.
A systematic review to evaluate the efficacy of oral LLLT for oral mucositis in children with cancer and the safety of oral LLLT in any age with cancer (International Prospective Register of Systematic Reviews/PROSPERO registration: CRD42018099772). Multiple databases and grey literature were screened. Randomised controlled trials were considered for assessing efficacy, and all studies were considered for assessing safety. Primary outcomes included severity of oral mucositis, oral pain and adverse events. Where results were compatible, meta-analysis was performed using a random-effects model. A narrative synthesis considered other outcome measures.
14 studies (n>416 children) were included in the narrative synthesis of LLLT efficacy. 5 studies (n=380 children and young people) were included in the meta-analyses. Results demonstrate that LLLT may reduce the severity of oral mucositis and the level of oral pain, but further randomised controlled trials are needed to confirm or deny this. There is vast variation in different trial protocols. Insufficient blinding between LLLT or sham therapy/control led to a strong risk of performance bias. 75 studies (encompassing 2712 patients of all ages who had undergone LLLT) demonstrated minor and infrequent adverse reactions, but most studies had significant areas of weakness in quality.
LLLT appears to be a safe therapy, but further evidence is needed to assess its efficacy as a prevention or treatment tool for oral mucositis in children with cancer.
评估口服低水平激光疗法(LLLT),又称光生物调节,在减少癌症接受化疗的儿童和青少年口腔粘膜炎方面的疗效。
系统评价评估口服 LLLT 对癌症儿童口腔粘膜炎的疗效和任何年龄癌症患者口服 LLLT 的安全性(国际前瞻性注册系统评价/PROSPERO 注册:CRD42018099772)。筛选了多个数据库和灰色文献。随机对照试验被认为是评估疗效的,所有研究都被认为是评估安全性的。主要结局包括口腔粘膜炎的严重程度、口腔疼痛和不良事件。如果结果兼容,使用随机效应模型进行荟萃分析。叙述性综合考虑了其他结局测量。
纳入了 14 项研究(n>416 名儿童),对 LLLT 疗效进行了叙述性综合分析。5 项研究(n=380 名儿童和青少年)纳入了荟萃分析。结果表明,LLLT 可能降低口腔粘膜炎的严重程度和口腔疼痛的程度,但需要进一步的随机对照试验来证实或否定这一点。不同试验方案存在很大差异。LLLT 或假治疗/对照组之间的 blinding 不足导致了很强的性能偏差风险。75 项研究(涵盖了所有年龄接受 LLLT 的 2712 名患者)显示出轻微和罕见的不良反应,但大多数研究在质量方面存在显著的弱点。
LLLT 似乎是一种安全的治疗方法,但需要进一步的证据来评估其作为癌症儿童口腔粘膜炎预防或治疗工具的疗效。